Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT) -- Ignore unavailable to you. Want to Upgrade?

To: R Sandvig who wrote (281)	5/27/1998 4:55:00 PM
From: Dennis	Read Replies (1) \| Respond to of 687

You certainly don't owe me any apologies, but it is nice to hear some simple manners at SI. Many of the threads can be a bit hostile when the markets are nervous. I guess the market liked the mdt earnings, I tried to add today but did not get filled. I have been in mdt for about 2 years. It was highly recommended to me by my FORMER broker at Paine Webber. We have since departed company. gg The future looks bright for mdt and management seems to be on the ball. What is your outlook?? FWIW, I am far from an expert on this company. ANYONE ELSE OUT THERE??? Thanks in advance

To: R Sandvig who wrote (281)	6/5/1998 4:45:00 PM
From: Dennis	Respond to of 687

HOPE THIS MAKES YOU FEEL BETTER :o) Wednesday June 3, 11:44 am Eastern Time Medtronic rises on earnings outlook CHICAGO, June 3 (Reuters) - Shares in Medtronic Inc. jumped 1-13/16 to 55-7/8 after the company received approval for a new stent and expressed comfort with analysts' earnings estimates. The company is comfortable with analysts' consensus earnings estimates of about $1.50 per share for fiscal 1999 and about $1.77 per share for fiscal 2000, said a spokesman. That statement, made earlier Wednesday by Medtronic chief executive William George at a conference in New York, likely boosted the stock, said an industry analyst. Medtronic also received U.S. Food and Drug Administration clearance Wednesday for its Wiktor Rival stent system. The FDA approval had been expected, analysts said.